Switch theme
Sign up to access all valuation multiples
Suraksha Diagnostic Ltd offers a one-stop integrated solution for pathology and radiology testing, and medical consultation services to its customers through its extensive operational network, consisting of its flagship central reference laboratory, approximately 8 satellite laboratories, and 215 customer touchpoints which include 49 diagnostic centres, and 166 sample collection centres across the states of West Bengal, Bihar, Assam, and Meghalaya.
2005
1.5K+
LTM Revenue $30.4M
LTM EBITDA $9.9M
$204M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Suraksha Diagnostics has a last 12-month revenue (LTM) of $30.4M and a last 12-month EBITDA of $9.9M.
In the most recent fiscal year, Suraksha Diagnostics achieved revenue of $29.5M and an EBITDA of $10.0M.
Suraksha Diagnostics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Suraksha Diagnostics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $30.4M | XXX | $29.5M | XXX | XXX | XXX |
| Gross Profit | $27.4M | XXX | $26.1M | XXX | XXX | XXX |
| Gross Margin | 90% | XXX | 88% | XXX | XXX | XXX |
| EBITDA | $9.9M | XXX | $10.0M | XXX | XXX | XXX |
| EBITDA Margin | 33% | XXX | 34% | XXX | XXX | XXX |
| EBIT | $5.7M | XXX | $5.6M | XXX | XXX | XXX |
| EBIT Margin | 19% | XXX | 19% | XXX | XXX | XXX |
| Net Profit | $3.8M | XXX | $3.7M | XXX | XXX | XXX |
| Net Margin | 13% | XXX | 13% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $0.4M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Suraksha Diagnostics's stock price is INR 321 (or $4).
Suraksha Diagnostics has current market cap of INR 16.7B (or $196M), and EV of INR 17.4B (or $204M).
See Suraksha Diagnostics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $204M | $196M | XXX | XXX | XXX | XXX | $0.07 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Suraksha Diagnostics has market cap of $196M and EV of $204M.
Suraksha Diagnostics's trades at 7.1x EV/Revenue multiple, and 21.2x EV/EBITDA.
Equity research analysts estimate Suraksha Diagnostics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Suraksha Diagnostics has a P/E ratio of 50.9x.
See valuation multiples for Suraksha Diagnostics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $196M | XXX | $196M | XXX | XXX | XXX |
| EV (current) | $204M | XXX | $204M | XXX | XXX | XXX |
| EV/Revenue | 6.7x | XXX | 7.1x | XXX | XXX | XXX |
| EV/EBITDA | 20.5x | XXX | 21.2x | XXX | XXX | XXX |
| EV/EBIT | 35.7x | XXX | 37.5x | XXX | XXX | XXX |
| EV/Gross Profit | 7.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | 50.9x | XXX | 56.2x | XXX | XXX | XXX |
| EV/FCF | 63.9x | XXX | 87.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSuraksha Diagnostics's last 12 month revenue growth is 18%
Suraksha Diagnostics's revenue per employee in the last FY averaged $20K, while opex per employee averaged $14K for the same period.
Suraksha Diagnostics's rule of 40 is 52% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Suraksha Diagnostics's rule of X is 78% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Suraksha Diagnostics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 18% | XXX | 18% | XXX | XXX | XXX |
| EBITDA Margin | 33% | XXX | 34% | XXX | XXX | XXX |
| EBITDA Growth | 24% | XXX | 18% | XXX | XXX | XXX |
| Rule of 40 | 52% | XXX | 52% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 78% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $20K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $14K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 69% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Burjeel Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| PureHealth | XXX | XXX | XXX | XXX | XXX | XXX |
| Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Ramsay Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Athens Medical Centre | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Suraksha Diagnostics acquired XXX companies to date.
Last acquisition by Suraksha Diagnostics was XXXXXXXX, XXXXX XXXXX XXXXXX . Suraksha Diagnostics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Suraksha Diagnostics founded? | Suraksha Diagnostics was founded in 2005. |
| Where is Suraksha Diagnostics headquartered? | Suraksha Diagnostics is headquartered in India. |
| How many employees does Suraksha Diagnostics have? | As of today, Suraksha Diagnostics has 1.5K+ employees. |
| Is Suraksha Diagnostics publicy listed? | Yes, Suraksha Diagnostics is a public company listed on NSE. |
| What is the stock symbol of Suraksha Diagnostics? | Suraksha Diagnostics trades under SURAKSHA ticker. |
| When did Suraksha Diagnostics go public? | Suraksha Diagnostics went public in 2024. |
| Who are competitors of Suraksha Diagnostics? | Similar companies to Suraksha Diagnostics include e.g. Burjeel Holdings, PureHealth, Integral Diagnostics, Ramsay Health. |
| What is the current market cap of Suraksha Diagnostics? | Suraksha Diagnostics's current market cap is $196M |
| What is the current revenue of Suraksha Diagnostics? | Suraksha Diagnostics's last 12 months revenue is $30.4M. |
| What is the current revenue growth of Suraksha Diagnostics? | Suraksha Diagnostics revenue growth (NTM/LTM) is 18%. |
| What is the current EV/Revenue multiple of Suraksha Diagnostics? | Current revenue multiple of Suraksha Diagnostics is 6.7x. |
| Is Suraksha Diagnostics profitable? | Yes, Suraksha Diagnostics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Suraksha Diagnostics? | Suraksha Diagnostics's last 12 months EBITDA is $9.9M. |
| What is Suraksha Diagnostics's EBITDA margin? | Suraksha Diagnostics's last 12 months EBITDA margin is 33%. |
| What is the current EV/EBITDA multiple of Suraksha Diagnostics? | Current EBITDA multiple of Suraksha Diagnostics is 20.5x. |
| What is the current FCF of Suraksha Diagnostics? | Suraksha Diagnostics's last 12 months FCF is $3.2M. |
| What is Suraksha Diagnostics's FCF margin? | Suraksha Diagnostics's last 12 months FCF margin is 10%. |
| What is the current EV/FCF multiple of Suraksha Diagnostics? | Current FCF multiple of Suraksha Diagnostics is 63.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
